Current Atherosclerosis Reports最新文献

"Improving Diet Quality of Children with Dyslipidemia Who also Exhibit Picky Eating Behaviors". "改善同时表现出挑食行为的血脂异常儿童的饮食质量"。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-09-26 DOI: 10.1007/s11883-024-01242-2

Janet Carter

引用次数: 0

Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment. 针对动脉粥样硬化的炎症通路：探索治疗新机遇。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-10-15 DOI: 10.1007/s11883-024-01241-3

Alessia d'Aiello, Simone Filomia, Mattia Brecciaroli, Tommaso Sanna, Daniela Pedicino, Giovanna Liuzzo

{"title":"Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment.","authors":"Alessia d'Aiello, Simone Filomia, Mattia Brecciaroli, Tommaso Sanna, Daniela Pedicino, Giovanna Liuzzo","doi":"10.1007/s11883-024-01241-3","DOIUrl":"10.1007/s11883-024-01241-3","url":null,"abstract":"Purpose of the review: This review discusses the molecular mechanisms involved in the immuno-pathogenesis of atherosclerosis, the pleiotropic anti-inflammatory effects of approved cardiovascular therapies and the available evidence on immunomodulatory therapies for atherosclerotic cardiovascular disease (ACVD). We highlight the importance of clinical and translational research in identifying molecular mechanisms and discovering new therapeutic targets.Recent findings: The CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial was the first to demonstrate a reduction in cardiovascular (CV) risk with anti-inflammatory therapy, irrespective of serum lipid levels. ACVD is the leading cause of death worldwide. Although targeting principal risk factors significantly reduces CV risk, residual risk remains unaddressed. The immunological mechanisms underlying atherosclerosis represent attractive therapeutic targets. Several commonly used and non-primarily anti-inflammatory drugs (i.e. SGLT2i, and PCSK9i) exhibit pleiotropic properties. Otherwise, recent trials have investigated the blockade of primarily inflammatory compounds, trying to lower the residual risk via low-dose IL-2, PTPN22 and CD31 pathway modulation. In the era of precision medicine, modern approaches may explore new pharmacological targets, identify new markers of vascular inflammation, and evaluate therapeutic responses.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myopathy in Statin-Treated Children and Adolescents: A Practical Approach. 他汀类药物治疗的儿童和青少年的肌病：实用方法。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-09-24 DOI: 10.1007/s11883-024-01239-x

Rae-Ellen W Kavey

引用次数: 0

PCSK9 Monoclonal Antibodies Have Come a Long Way. PCSK9 单克隆抗体取得了长足进步。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-10-10 DOI: 10.1007/s11883-024-01243-1

Sandra Zendjebil, Philippe Gabriel Steg

引用次数: 0

Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care. 让患有血脂紊乱症的青少年和年轻人过渡到成人医疗保健。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-10-02 DOI: 10.1007/s11883-024-01244-0

Christopher Schmitt, Thomas M Yohannan

引用次数: 0

Pericoronary Fat Attenuation: Diagnosis and Clinical Implications. 冠状动脉周围脂肪衰减：诊断与临床意义。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-10-10 DOI: 10.1007/s11883-024-01245-z

Malek Nayfeh, Maria Alwan, Ahmed Sayed, Mouaz H Al-Mallah

{"title":"Pericoronary Fat Attenuation: Diagnosis and Clinical Implications.","authors":"Malek Nayfeh, Maria Alwan, Ahmed Sayed, Mouaz H Al-Mallah","doi":"10.1007/s11883-024-01245-z","DOIUrl":"10.1007/s11883-024-01245-z","url":null,"abstract":"Purpose of the review: The purpose of this review is to evaluate the current state of knowledge regarding the technical challenges associated with the Post-Acquisition Fat Attenuation Index (PFAI). By examining the limitations and gaps in the current methodologies, this review aims to provide a comprehensive understanding of how various factors impact the accuracy and reliability of PFAI measurements.Recent findings: PFAI correlates with plaque instability, as inflammation in coronary plaque alters surrounding adipose tissue composition, increasing its water content and reducing lipid content, which is detectable via cardiac CT as increased attenuation. Recent studies have demonstrated PFA's prognostic value, with elevated levels linked to higher risks of cardiac events and plaque instability. A 2022 meta-analysis confirmed its association with major adverse cardiac events. Machine learning algorithms incorporating PFA and additional imaging features have further enhanced risk prediction beyond traditional metrics. Pericoronary fat attenuation is a promising marker for assessing coronary inflammation and could be useful in predicting plaque development, rupture, and monitoring treatment response, though further prospective studies and technical standardization are needed to fully establish its clinical benefits.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where? 对患有血脂异常的青少年进行营养干预：谁、做什么、何时、何地？

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-01 Epub Date: 2024-10-23 DOI: 10.1007/s11883-024-01236-0

Maya Rashad, Lauren Williams, Don P Wilson

{"title":"Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?","authors":"Maya Rashad, Lauren Williams, Don P Wilson","doi":"10.1007/s11883-024-01236-0","DOIUrl":"10.1007/s11883-024-01236-0","url":null,"abstract":"Purposeof review: A heart-healthy lifestyle adopted during childhood and sustained throughout life can reduce cardiovascular disease risk in youth with dyslipidemia. In this review, we discuss nutrition recommendations for youth (< 18 years-of-age) with dyslipidemia, compare recommendations for youth versus those for adults, review published data regarding nutrition management in the pediatric population, and discuss strategies for successful implementation in a clinical setting.Recent findings: Recent publications highlight the characteristics of genetic and acquired hypertriglyceridemia disorders, dietary adjuncts used for lipid-lowering, and the effectiveness of a multi-disciplinary team approach. Nutrition interventions remain a cornerstone of lipid management and cardiovascular disease risk reduction in youth with dyslipidemia. Nutrition counseling should include age and developmentally appropriate education while also addressing barriers to implementing a heart-healthy lifestyle. A registered dietitian nutritionist plays an important role within a multidisciplinary clinic setting by providing dietary recommendations to address the needs of youth with dyslipidemia.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Health Data Sciences and Cardiovascular Disease in Africa: Needs and the Way Forward. 非洲的健康数据科学与心血管疾病：需求与未来之路》。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-01 Epub Date: 2024-09-06 DOI: 10.1007/s11883-024-01235-1

Maha Inam, Sana Sheikh, Adeel Khoja, Amina Abubakar, Reena Shah, Zainab Samad, Anthony Ngugi, Farhana Alarakhiya, Akbar Waljee, Salim S Virani

{"title":"Health Data Sciences and Cardiovascular Disease in Africa: Needs and the Way Forward.","authors":"Maha Inam, Sana Sheikh, Adeel Khoja, Amina Abubakar, Reena Shah, Zainab Samad, Anthony Ngugi, Farhana Alarakhiya, Akbar Waljee, Salim S Virani","doi":"10.1007/s11883-024-01235-1","DOIUrl":"10.1007/s11883-024-01235-1","url":null,"abstract":"Purpose of review: The rising burden of cardiovascular disease (CVD) in Africa is of great concern. Health data sciences is a rapidly developing field which has the potential to improve health outcomes, especially in low-middle income countries with burdened healthcare systems. We aim to explore the current CVD landscape in Africa, highlighting the importance of health data sciences in the region and identifying potential opportunities for application and growth by leveraging health data sciences to improve CVD outcomes.Recent findings: While there have been a number of initiatives aimed at developing health data sciences in Africa over the recent decades, the progress and growth are still in their early stages. Its maximum potential can be leveraged through adequate funding, advanced training programs, focused resource allocation, encouraging bidirectional international partnerships, instituting best ethical practices, and prioritizing data science health research in the region. The findings of this review explore the current landscape of CVD and highlight the potential benefits and utility of health data sciences to address CVD challenges in Africa. By understanding and overcoming the barriers associated with health data sciences training, research, and application in the region, focused initiatives can be developed to promote research and development. These efforts will allow policymakers to form informed, evidence-based frameworks for the prevention and management of CVDs, and ultimately result in improved CVD outcomes in the region.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should We Use Aspirin or P2Y₁₂ Inhibitor Monotherapy in Stable Ischemic Heart Disease? 稳定型缺血性心脏病应该使用阿司匹林还是 P2Y12 抑制剂单药治疗？

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-01 Epub Date: 2024-09-07 DOI: 10.1007/s11883-024-01234-2

Rishi Chandiramani, Adhya Mehta, Roger S Blumenthal, Marlene S Williams

{"title":"Should We Use Aspirin or P2Y12 Inhibitor Monotherapy in Stable Ischemic Heart Disease?","authors":"Rishi Chandiramani, Adhya Mehta, Roger S Blumenthal, Marlene S Williams","doi":"10.1007/s11883-024-01234-2","DOIUrl":"10.1007/s11883-024-01234-2","url":null,"abstract":"Purpose of review: To summarize the recent evidence and guideline recommendations on aspirin or P2Y12 inhibitor monotherapy in patients with stable ischemic heart disease and provide insights into future directions on this topic, which involves transition to a personalized assessment of bleeding and thrombotic risks.Recent findings: It has been questioned whether the evidence for aspirin as the foundational component of secondary prevention in patients with coronary artery disease aligns with contemporary pharmaco-invasive strategies. The recent HOST-EXAM study randomized patients who had received dual antiplatelet therapy for 6 to 18 months without ischemic or major bleeding events to either clopidogrel or aspirin for a further 24 months, and demonstrated that the patients in the clopidogrel arm had significantly lower rates of both thrombotic and bleeding complications compared to those in the aspirin arm. The patient-level PANTHER meta-analysis showed that in patients with established coronary artery disease, P2Y12 inhibitor monotherapy was associated with lower rates of myocardial infarction, stent thrombosis as well as gastrointestinal bleeding and hemorrhagic stroke compared to aspirin monotherapy, albeit with similar rates of all-cause mortality, cardiovascular mortality and major bleeding. Long-term low-dose aspirin is recommended for secondary prevention in patients with stable ischemic heart disease, with clopidogrel monotherapy being acknowledged as a feasible alternative. Dual antiplatelet therapy for six months after percutaneous coronary intervention remains the standard recommendation for patients with stable ischemic heart disease. However, the duration of dual antiplatelet therapy may be shortened and followed by P2Y12 inhibitor monotherapy or prolonged based on individualized evaluation of the patient's risk profile.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice? 临床实践中，青少年心血管健康管理的家族史是否仍有意义？

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-01 Epub Date: 2024-08-27 DOI: 10.1007/s11883-024-01232-4

Daphney Kernizan, Sean Connolly, Dima Turpin, Abbas Zaidi, Carissa M Baker-Smith

{"title":"Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?","authors":"Daphney Kernizan, Sean Connolly, Dima Turpin, Abbas Zaidi, Carissa M Baker-Smith","doi":"10.1007/s11883-024-01232-4","DOIUrl":"10.1007/s11883-024-01232-4","url":null,"abstract":"Purpose of review: Family history of premature cardiovascular disease is a strong predictor of individual cardiovascular risk. However, family history is not always available and not always reliable. Roughly 80% of health outcomes are influenced not by genetic risk but by societal factors, including adverse health behaviors and environment. Furthermore, in the present age of genetic testing, laboratory evaluations, and imaging, a key question remains: What is the contemporary relevance of family history screening in the management of cardiovascular disease in youth?Recent findings: Knowledge of an individual's family history can help clinicians identify not only inherited risk but also familial clustering of unhealthy behaviors and environmental adversity contributing to enhanced cardiovascular disease risk in youth. For those at greatest risk, prevention strategies can be applied sooner and more conservatively. Integrating family history into clinical practice is crucial for cardiovascular risk assessment and for optimizing outcomes, but, in some cases, is more reflective of social factors.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0